Therefore, a well‐known NLRP3 inhibitor, colchicine, appears to be promising to be repurposed for the treatment of COVID‐19, especially in patients with concurrent obesity or diabetes. The gene discussed is NLRP3; the disease is obesity due to melanocortin 4 receptor deficiency.